Peptide5 (TFA)

OC(C(F)(F)F)=O.C[C@@H](O)[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC2=CC=CC=C2)NC([C@H](CS)NC([C@H](CC(O)=O)NC([C@H](C(C)C)N)=O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)=O

[1]Simon J O'Carroll, et al. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008 May;15 (1) :27-42.|[2]Yilin Mao, et al. Characterisation of Peptide5 systemic administration for treating traumatic spinal cord injured rats. Exp Brain Res. 2017 Oct;235 (10) :3033-3048.|[3]Tonkin RS, et al. Attenuation of mechanical pain hypersensitivity by treatment with Peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice. Exp Neurol. 2018 Feb;300:1-12.